The Pharm

In October 2026, The Pharm concentrated 98.90% of sales in Flower while Pre-Roll accounted for 0.66%, with Flower down 19.54% year over year and 19.81% month over month. Despite a 6,422.26% year-over-year surge and 120.06% month-over-month jump in Pre-Roll, the category’s sub-1% share could not offset a brand-level sales decline of 19.35% year over year; the average price fell 7.77% year over year to $14.89, indicating mix pressure rather than price-led volume expansion. The brand’s Flower rank stood at 14 in Arizona, and with Flower averaging $15.16 versus Pre-Roll at $4.00, the mix skew implies that unit growth in lower-priced formats is too small to counteract volume contraction in the core. The pattern implies that October 2026 performance was governed by core-category retrenchment, where a deep but narrow portfolio amplified downside when Flower softened.

The shift toward Pre-Roll—up 6,422.26% year over year and 120.06% month over month—signals early traction in an entry-price format, yet the 0.66% share alongside a 98.90% Flower reliance and a 19.81% month-over-month Flower decline suggests limited diversification benefit in the near term. With the brand positioned at rank 14 in Arizona Flower and Flower down 19.54% year over year, the current mix constrains rank mobility because momentum sits in a tiny category slice while the largest bucket contracts. The implication is that to improve standing and stabilize year-over-year trends, The Pharm needs either a reallocation that lifts Pre-Roll above low-single-digit share or a Flower strategy that trades less on price cuts (−7.77% year over year) and more on unit retention, as current pricing compression is not translating into sufficient volume capture.